The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Cytoplasmic Sequestration of Wild-Type p53 Protein Impairs the G 1 Checkpoint after DNA Damage
Open accessAbstract
Wild-type p53 protein is abnormally sequestered in the cytoplasm of a subset of primary human tumors including neuroblastomas (NB) (U. M. Moll, M. LaQuaglia, J. Benard, and G. Riou, Proc. Natl. Acad. Sci. USA 92:4407-4411, 1995; U. M. Moll, G. Riou, and A. J. Levine, Proc. Natl. Acad. Sci.USA 89:7262-7266, 1992). This may represent a nonmutational mechanism for abrogating p53 tumor suppressor function. To test this hypothesis, we established the first available in vitro model that accurately reflects the wild-type p53 sequestration found in NB tumors. We characterized a series of human NB cell lines that overexpress wild-type p53 and show that p53 is preferentially localized to discrete cytoplasmic structures, with no detectable nuclear p53. These cell lines, when challenged with a variety of DNA strand-breaking agents, all exhibit impaired p53-mediated G1 arrest. Induction analysis of p53 and p53-responsive genes show that this impairment is due to suppression of nuclear p53 accumulation. Thus, this naturally occurring translocation defect compromises the suppressor function of p53 and likely plays a role in the tumorigenesis of these tumors previously thought to be unaffected by p53 alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citationKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
A Detergent‐trypsin method for the preparation of nuclei for flow cytometric DNA analysis
Vindeløv, L. L., Christensen, I. J., & Nissen, N. I. (1983) · Cytometry · doi:10.1002/cyto.990030503 · Cited by 1,639
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,332
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,197
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
Debbas, M., & White, E. (1993) · Genes & Development · doi:10.1101/gad.7.4.546 · Cited by 871
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Nelson, W. G., & Kastan, M. B. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1815 · Cited by 857
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Induction of WAF1/CIP1 by a p53-independent pathway.
Michieli, P., Chedid, M., Lin, D. P., Pierce, J. H., Mercer, W. E., & Givol, D. (1994) · PubMed · Cited by 768
Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis
Speir, E., Modali, R., Huang, E.-S., Leon, M. B., Shawl, F., Finkel, T., & Epstein, S. E. (1994) · Science · doi:10.1126/science.8023160 · Cited by 753
A transcriptionally active DNA-binding site for human p53 protein complexes.
Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., & Shay, J. W. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2866 · Cited by 732
Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., & Harris, C. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2230 · Cited by 665
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Moll, U. M., Riou, G., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7262 · Cited by 575
Self-citationInhibition of p53 transactivation required for transformation by adenovirus early 1B protein
Yew, P. R., & Berk, A. J. (1992) · Nature · doi:10.1038/357082a0 · Cited by 561
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.
Martinez, J., Georgoff, I., Martinez, J., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.2.151 · Cited by 527
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells.
Oren, M., Maltzman, W., & Levine, A. J. (1981) · Molecular and Cellular Biology · doi:10.1128/mcb.1.2.101 · Cited by 489
Moll, U. M., LaQuaglia, M., Bénard, J., & Riou, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4407 · Cited by 427
Self-citationFunctional inactivation but not structural mutation of p53 causes liver cancer
Ueda, H., Ullrich, S. J., Gangemi, J. D., Kappel, C. A., Ngo, L., Feitelson, M. A., & Jay, G. (1995) · Nature Genetics · doi:10.1038/ng0195-41 · Cited by 367
Mietz, J. A., Unger, T., Huibregtse, J. M., & Howley, P. M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05608.x · Cited by 365
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Juven‐Gershon, T., Barak, Y., Zauberman, A., George, D. L., & Oren, M. (1993) · PubMed · Cited by 332
Aberrant Subcellular Localization of BRCA1 in Breast Cancer
Chen, Y., Chen, C.-F., Riley, D. J., Allred, D. C., Chen, P.-L., Von Hoff, D., Osborne, C. K., & Lee, W.-H. (1995) · Science · doi:10.1126/science.270.5237.789 · Cited by 309
Feitelson, M. A., Zhu, M., Duan, L., & London, W. T. (1993) · PubMed · Cited by 307
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
Davidoff, A. M., Iglehart, J. D., & Marks, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3439 · Cited by 272
Melino, G., Annicchiarico-Petruzzelli, M., Piredda, L., Candi, E., Gentile, V, Davies, P. J., & Piacentini, M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6584 · Cited by 265
Monoclonal antibody analysis of p53 expression in normal and transformed cells
Yewdell, J. W., Gannon, J. V., & Lane, D. P. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.444-452.1986 · Cited by 264
Wagner, I., Arlt, H., van Dyck, L., Langer, T., & Neupert, W. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06843.x · Cited by 243
Hinds, P. W., Finlay, C. A., Frey, A. B., & Levine, A. J. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2863 · Cited by 232
Passage of viral membrane proteins through the Golgi complex
Green, J., Griffiths, G., Louvard, D., Quinn, P., & Warren, G. (1981) · Journal of Molecular Biology · doi:10.1016/0022-2836(81)90122-4 · Cited by 206
Nuclear localization is essential for the activity of p53 protein.
Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J., & Rotter, V. (1991) · PubMed · Cited by 192
Cannon, J. V., & Lane, D. P. (1991) · Nature · doi:10.1038/349802a0 · Cited by 173
Demers, G. W., Foster, S. A., Halbert, C. L., & Galloway, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4382 · Cited by 172
Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.
Shaulsky, G., Ben‐Ze'ev, A., & Rotter, V. (1990) · PubMed · Cited by 166
Chen, J. W., Cha, Y., Yuksel, K. U., Gracy, R. W., & August, J. T. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68370-x · Cited by 159
White, E. (1994) · Nature · doi:10.1038/371021a0 · Cited by 150
Ginsberg, D., Michael, D., Ginsberg, D., & Oren, M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.582 · Cited by 142
Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines.
Davidoff, A. M., Pence, J. C., Shorter, N. A., Iglehart, J. D., & Marks, J. R. (1992) · PubMed · Cited by 114
Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest.
Lin, D. P., Fiscella, M., O'Connor, P. M., Jackman, J., Chen, M., Luo, L. L., Sala, A., Travali, S., Appella, E., & Mercer, W. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.10079 · Cited by 104
p53 Is Covalently Linked to 5.8S rRNA
Fontoura, B. M. A., Sorokina, E. A., David, E., & Carroll, R. B. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5145 · Cited by 101
Regulation of p53 protein expression in human breast cancer cell lines
Vojtěšek, B., & Lane, D. P. (1993) · Journal of Cell Science · doi:10.1242/jcs.105.3.607 · Cited by 84
The Relationship of DNA Double-strand Break Induction to Radiosensitivity in Human Tumour Cell Lines
McMillan, T. J., Cassoni, A. M., Edwards, S. M., et al. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014551781 · Cited by 74
Kulesz-Martin, M. F., Lisafeld, B., Huang, H., Kisiel, N. D., & Lee, L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1698 · Cited by 71
Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions.
Negrini, M., Sabbioni, S., Haldar, S., Possati, L., Castagnoli, A., Corallini, A., Bròdano, G. B., & Croce, C. M. (1994) · PubMed · Cited by 55
Involvement of wild-type p53 protein in the cell cycle requires nuclear localization.
Shaulsky, G., Goldfinger, N., Peled, A., & Rotter, V. (1991) · PubMed · Cited by 53
Bueso-Ramos, C., Manshouri, T., Haidar, M. A., Huh, Y. O., Keating, M. J., & Albitar, M. X. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509051698 · Cited by 51
Takahashi, K., Sumimoto, H., Suzuki, K., & Ono, T. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940080112 · Cited by 39
Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells.
Sidell, N., & Koeffler, H. (1988) · PubMed · Cited by 33
N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatment
Livingstone, A., Mairs, R., Russell, J., O’Donoghue, J. A., Gaze, M. N., & Wheldon, T. E. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90260-7 · Cited by 18
DNA-binding Properties of the p53 Tumor Suppressor ProteinPreprint
Prives, C. L., Bargonetti, J., Farmer, G., Ferrari, E., Friedlander, P. A., Wang, Y., Jayaraman, L., Pavletich, N. P., & Hübscher, U. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.025 · Cited by 17
Cited by
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Death Signal-induced Localization of p53 Protein to Mitochondria
Marchenko, N. D., Zaika, A., & Moll, U. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.16202 · Cited by 901
Self-citationStommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
Self-citationTwenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
Metadata
- Authors
- Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M., & Zambetti, G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1996-03
- Volume
- 16
- Issue
- 3
- Pages
- 1126-1137
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W1746080159
- Cited by
- 277
- References
- 63
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.